Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.86 |
| ▸ | PRSS1 | P07477 | 18/20 | 0.86 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.85 |
| ▸ | F2 | P00734 | 5/20 | 0.82 |
| ▸ | PLG | P00747 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542917 | 1.00 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL13160832 | 0.93 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL15489295 | 0.93 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL12447697 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL12589586 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL29426323 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL52983 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL16588897 | 0.91 | F10 (0.98) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL7890763 | 0.91 | F10 (0.98) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL12589582 | 0.88 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993464-B2 | Otamixaban formulations with improved stability | SANOFI (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20170224668-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | SANOFI (FR) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224668-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | F12, F11, PROC | F10 4/4885PRSS1 939/4885TMPRSS2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.